Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Amortizatization of Intangibles (2016 - 2025)

Historic Amortizatization of Intangibles for Agios Pharmaceuticals (AGIO) over the last 14 years, with Q3 2025 value amounting to $3.1 million.

  • Agios Pharmaceuticals' Amortizatization of Intangibles fell 236.69% to $3.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.8 million, marking a year-over-year increase of 2772.09%. This contributed to the annual value of $14.5 million for FY2024, which is 3513.06% up from last year.
  • According to the latest figures from Q3 2025, Agios Pharmaceuticals' Amortizatization of Intangibles is $3.1 million, which was down 236.69% from $3.1 million recorded in Q2 2025.
  • Agios Pharmaceuticals' Amortizatization of Intangibles' 5-year high stood at $5.6 million during Q4 2024, with a 5-year trough of $2.2 million in Q3 2023.
  • In the last 5 years, Agios Pharmaceuticals' Amortizatization of Intangibles had a median value of $2.8 million in 2023 and averaged $2.8 million.
  • Its Amortizatization of Intangibles has fluctuated over the past 5 years, first tumbled by 1130.12% in 2023, then surged by 10399.56% in 2024.
  • Over the past 5 years, Agios Pharmaceuticals' Amortizatization of Intangibles (Quarter) stood at $2.4 million in 2021, then rose by 6.44% to $2.6 million in 2022, then grew by 7.41% to $2.8 million in 2023, then skyrocketed by 104.0% to $5.6 million in 2024, then crashed by 44.18% to $3.1 million in 2025.
  • Its Amortizatization of Intangibles was $3.1 million in Q3 2025, compared to $3.1 million in Q2 2025 and $3.0 million in Q1 2025.